-
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results
Monday, December 8, 2025 - 2:06pm | 596Read More...Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock is surging on Monday, after the company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. • Fulcrum Therapeutics shares are testing new highs. What’s driving FULC...
-
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
Tuesday, July 20, 2021 - 4:54pm | 615Read More...A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ: GRPH) just a few weeks after its IPO. BofA Securities on Graphite Bio Analyst Geoff Meacham initiated the firm’s coverage on Graphite with a...
-
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
Friday, June 11, 2021 - 10:33am | 264Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell disease. Presenting data from two trials at the European Hematology...
-
Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment
Thursday, April 8, 2021 - 7:20am | 386Read More...Global Blood Therapeutics Inc (NASDAQ: GBT) has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study evaluating Oxbryta (voxelotor) tablets in patients with sickle cell disease (SCD). The results showed a significant...
-
GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial
Monday, August 5, 2019 - 8:42am | 211Read More...GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoints. On Monday morning, a number of firms have downgraded the stock: Jefferies downgraded...
-
Global Blood Shares Weak Into ASCAT; Concern With Timeline Of Sickle Cell Treatment May Be Weighing
Wednesday, October 5, 2016 - 2:28pm | 343Read More...Global Blood Therapeutics Inc (NASDAQ: GBT) shares are down 7.4 percent Wednesday on no official news from the company. However, a source familiar with the matter has told Benzinga that investors are concerned that the company’s 28-day efficacy timeline for GBT440 may need to be extended to...
-
Sickle Cell Knocks Out NFL Player. Can these Companies Help?
Wednesday, January 4, 2012 - 1:41pm | 593Read More...Sickle cell disease is debilitating to millions of Americans, including Pittsburgh Steelers safety Ryan Clark. Although Clark only has one copy of the sickle cell gene - two are required for the full-blown disease - his body was adversely affected when him and his team traveled to high altitudes in...
